GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibitor Therapeutics Inc (OTCPK:INTI) » Definitions » 1-Year ROIIC %

Inhibitor Therapeutics (Inhibitor Therapeutics) 1-Year ROIIC % : 0.00% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Inhibitor Therapeutics 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Inhibitor Therapeutics does not have enough data to calculate 1-Year ROIIC %.


Inhibitor Therapeutics 1-Year ROIIC % Historical Data

The historical data trend for Inhibitor Therapeutics's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibitor Therapeutics 1-Year ROIIC % Chart

Inhibitor Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -786.15 14,075.00 486.09 -183.36 -

Inhibitor Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -183.36 - 420.42 - -

Competitive Comparison of Inhibitor Therapeutics's 1-Year ROIIC %

For the Biotechnology subindustry, Inhibitor Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibitor Therapeutics's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibitor Therapeutics's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Inhibitor Therapeutics's 1-Year ROIIC % falls into.



Inhibitor Therapeutics 1-Year ROIIC % Calculation

Inhibitor Therapeutics's 1-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -3.405 (Dec. 2023) - -0.655039 (Dec. 2022) )/( 0 (Dec. 2023) - 0.411 (Dec. 2022) )
=-2.749961/
=N/A%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Inhibitor Therapeutics  (OTCPK:INTI) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Inhibitor Therapeutics 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Inhibitor Therapeutics's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibitor Therapeutics (Inhibitor Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
900 West Platt Street, Suite 200, Tampa, FL, USA, 33606-2173
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.
Executives
Black Robe Capital Llc 10 percent owner 900 WEST PLATT STREET SUITE 200, TAMPA FL 33606
Ronald E Osman Irrevocable Trust Iii 10 percent owner 1602 WEST KIMMEL, P.O. BOX 939, MARION IL 62959
Ronald E Osman director, 10 percent owner 1602 KIMMEL STREET, MARION IL 62959
Donovan James Joseph Iii 10 percent owner C/O TPB 2012 LLC 12412 POWERSCOURT DR, SUITE 35, SAINT LOUIS MO 63131
Tpb 2012 Llc 10 percent owner 12412 POWERSCOURT DRIVE SUITE 35, SAINT LOUIS MO 63131
Michelle Yanez director 449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Niraj Vasisht director C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE., SUITE 225, RALEIGH NC 27612
James A Mcnulty 10 percent owner, officer: See Remarks C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mayne Pharma International Pty Ltd 10 percent owner 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Ventures Pty Ltd 10 percent owner 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Group Ltd 10 percent owner 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Garrison J. Hasara officer: CFO and Treasurer 324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Debra Peattie director 4830 W. KENNEDY BLVD., SUITE 600, TAMPA FL 33609
Robert Daniel Martin director C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
E. Brendan Magrab director, officer: Chairman of the Board C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606